Close menu




September 29th, 2022 | 12:01 CEST

Verbio, Kleos Space, KWS Saat - This news is moving share prices!

  • Space
  • Technology
  • Investments
Photo credits: pixabay.com

Increased uncertainties in geopolitics, rampant inflation with exploding commodity and energy prices, and higher interest rates are making it increasingly difficult for companies to meet the forecasts they issued at the beginning of the year. Recent examples include battery manufacturer Varta and real estate financier Hypoport, which had to withdraw their annual targets. In addition, however, a number of companies have been able to surprise on the upside despite all the challenges.

time to read: 3 minutes | Author: Carsten Mainitz
ISIN: VERBIO VER.BIOENERGIE ON | DE000A0JL9W6 , KLEOS SPACE CDI/1/1 | AU0000015588 , KWS SAAT KGAA INH O.N. | DE0007074007

Table of contents:


    KWS Saat - Growing revenue and rising margins

    Positive news came from the plant breeding and biotechnology company KWS Saat, which was founded in Klein Wanzleben back in 1856. Despite economic and political challenges, the world's fourth-largest seed producer grew in terms of net sales from agricultural crops. According to its preliminary, unaudited results for fiscal 2021/2022, net sales rose by 17% to around EUR 1.54 billion with an EBIT margin of around 10% - that is better than expected. By comparison, EBIT in the previous year was only EUR 137 million. KWS Saat's guidance held out the prospect of net sales growth of 10% and an EBIT margin of between 8% and 9%. Given the good business performance, the Executive Board and Supervisory Board will propose to the Annual Shareholders' Meeting on December 6, 2022, that a dividend of EUR 0.80 per share be distributed.

    For the current fiscal year 2022/2023, the SDAX-listed company plans further growth with increasing profitability. Sales are expected to increase by 7% to 9% on a comparable basis. According to the Company's headquarters, the EBIT margin is expected to range between 10% and 11%.

    Eva Kienle, Chief Financial Officer, commented on the results: "Our strong growth in the past fiscal year once again underlines the attractiveness and resilience of our business model as an innovative seed company. Despite considerable burdens from inflation-related cost increases, we were able to increase our operating result significantly. In the new fiscal year, we aim to continue growing while investing at a high level in research and development as a driver of sustainable, innovative strength. However, given the existing geopolitical risks, increasing weather extremes, and strong inflationary developments, we expect the general conditions for KWS to remain challenging."

    Kleos Space - Launch in October

    Shareholders in Kleos Space, the global market leader in radio-frequency reconnaissance, have had little to cheer about in recent months. The Luxembourg-based company, which also has subsidiaries in Australia, the US and the United Kingdom, has lost around 60% of its value since the beginning of the year. Currently, a bottom is forming in the area around AUD 0.30, which could form the basis for a subsequent upward movement. The fundamental conditions for rising prices have at least been created in recent months.

    The space-based earth observation company uses space technology to locate radio transmissions around the globe and can thus efficiently analyze and uncover illegal activities on land and at sea. This involves using satellite clusters to collect radio frequency data, transmitting it to the ground, analyzing it with AI-powered technology and delivering it to the relevant customer.

    Three clusters of four satellites each are still in space, but a fourth is to follow in October with the Observer Mission (KSF3) satellites, significantly upgrading data quality. Equipped with AIS, VHF and X-band payloads, the four satellites will increase Kleos Space's data collection capacity by up to 119 million sq km per day. In addition, the average daily overflight rate over the 15-degree latitude area can be significantly increased.

    The long-term goal of the experienced management is to maneuver up to 20 clusters into orbit. Due to geopolitical tensions, the issue of security will become increasingly important with surveillance from space. States, public institutions, and private companies should rely on the technology of the market leader in the future. A growing order book already in the first half of the year is the best proof of this. The analysts at First Berlin formulate a price target of AUD 1.60 for the share certificates, a potential of over 400%!

    Verbio - Double-digit share price gain after record year

    With double-digit price gains, investors celebrated the record year of the biofuel manufacturer Verbio, which ended on June 30. The Company, based in Zörbig, Saxony-Anhalt, reported that sales in the 2021/2022 financial year rose by 77% to around EUR 1.8 billion. At around EUR 503 million, the operating result (EBITDA) was around three times higher than in the previous year. Verbio benefited from higher sales prices for biodiesel and bioethanol.

    As in the previous year, a dividend of EUR 0.20 was proposed. The Board of Directors expects to achieve EBITDA in the order of EUR 300 million in the 2022/2023 financial year. That does not take into account additional negative effects as a result of the Ukraine war.

    The analysts at Hauck Aufhäuser Investment raised the price target from EUR 85 to EUR 90 and continue to rate the share as a "buy". Verbio continues to benefit from legal requirements for the production of food-based biofuels. A tightening of the rules is unlikely in the meantime.


    Uncertainties at the economic and political levels are growing. Nevertheless, Verbio and KWS Saat both posted strong annual figures. After a significant correction, the launch of the fourth cluster into space should boost the Kleos Space share. Analysts believe the stock has great potential.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Juliane Zielonka on December 1st, 2022 | 10:44 CET

    Aspermont, Twitter, Apple - Strong numbers, strong visions and marketplace power

    • Digitization
    • Commodities
    • Investments

    The Australian media company for the commodities industry has presented its latest figures. The results are impressive, with total revenue up 17% YOY, among other things. This industry pioneer illustrates just how valuable access to high-quality information can be. Perhaps soon to disappear from the scene is Elon Musk's Twitter: Find out how strong its dependence on the App Store giant is and what impact Apple fees may have on its revenue model here.

    Read

    Commented by Fabian Lorenz on November 30th, 2022 | 13:31 CET

    Biotech stocks in focus: Morphosys, Evotec, Bayer, BioNxt Solutions

    • Biotechnology
    • Cancer
    • Investments

    Biotech stocks have struggled in 2022. In Germany, BioNTech has overtaken the previous heavyweights Morphosys and Evotec in record time. Morphosys shocked investors with data on its Alzheimer's hope. Analysts lowered their thumbs, and short-sellers discovered the stock for themselves. Evotec has been quiet this year. Analysts think the valuation is attractive, but meeting earnings guidance in the current year is not a given. BioNxt shares have jumped recently, and if the positive newsflow continues into 2023, a re-rating is possible. At Bayer, the pharmaceuticals division is also developing positively. Conclusion: investors should position themselves for the biotech year 2023.

    Read

    Commented by Armin Schulz on November 30th, 2022 | 10:57 CET

    Alibaba, Kleos Space, Plug Power - Turnaround candidates with potential

    • Space
    • ecommerce
    • Energy
    • Satellites

    In the wake of the recent stock market rally, some stocks have fallen behind. While the market has been optimistic about the future of some stocks, others have not had the same success. For investors looking for a potential turnaround stock, we have picked three companies worth considering. Each company has its own challenges and opportunities, and investors should do their due diligence before investing. With the right timing and strategy, these companies could be well poised for a comeback in the not-too-distant future.

    Read